Alnylam Inks $93M Japanese Deal

Xconomy Boston — 

Alnylam Pharmaceuticals (NASDAQ: ALNY) announced it has forged an alliance with Japan’s Kyowa Hakko Kogyo to commercialize the Cambridge, MA-based firm’s RNAi-based treatment for respiratory syncytial virus in Japan and other major Asian markets. The deal calls for Kyowa Hakko to pay Alnylam $15 million upfront, with as much as $78 million in development and sales milestone payments, plus royalties, on the table.